Accession Number: | 0001104659-22-072176 |
Date: | 2022-06-15 |
Issuer: | ELOXX PHARMACEUTICALS, INC. (ELOX) |
Original Submission Date: |
KARIV TOMER
C/O ELOXX PHARMACEUTICALS, INC
480 ARSENAL WAY, SUITE 130
WATERTOWN, MA 02472
Title of Security | Transaction Date | 2a. Deemed Execution Date | Transaction Code | Shares | Acquired or Disposed | Price per share | 5. Amount of Securities Beneficially Owned Following Reported Transaction | 6. Ownership Form Direct or Indirect | Nature of Indirect Ownership |
---|
Title of Derivative Security | Conversion or Exercise Price of Derivative Security | Transaction Date | Deemed Execution Date | Transaction Code | Number of Derivative Securities Acquired (A) or Disposed of (D) | Date Exercisable | Expiration Date | Title and Amount of Securities Underlying Derivative Security | Price of Derivative Security | Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | Ownership Form: Direct (D) or Indirect (I) | Nature of Indirect Beneficial Ownership |
---|---|---|---|---|---|---|---|---|---|---|---|---|
STOCK OPTIONS (RIGHT TO BUY) | 0.26 | 2022-06-15 | deemed execution date | A | 20,000 (a) | 2032-06-15 | common stock 20,000 | $0.26 | 20,000 | direct |
ID | footnote |
---|---|
f1 | the stock option vests as to 50% of the underlying shares on june 15, 2023 and the remainder in twelve (12) equal monthly installments thereafter. |
f2 | the reporting person will assign the economic interests of this grant to the pontifax funds, where he serves as a director of the general partner. |